LAVA Therapeutics’ (LVTX) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a research report report published on Thursday, Marketbeat reports. The brokerage currently has a $1.50 price objective on the stock, down from their prior price objective of $2.00.

LVTX has been the subject of several other reports. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Leerink Partners reissued a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Finally, JMP Securities reissued a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $3.17.

LAVA Therapeutics Price Performance

Shares of NASDAQ LVTX opened at $1.29 on Thursday. LAVA Therapeutics has a 12 month low of $0.85 and a 12 month high of $6.47. The company has a market cap of $33.91 million, a price-to-earnings ratio of -1.25 and a beta of 0.57. The business has a fifty day simple moving average of $1.00 and a 200-day simple moving average of $1.43.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Tuesday, December 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.11). As a group, sell-side analysts expect that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

Institutional Investors Weigh In On LAVA Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in LVTX. Virtu Financial LLC purchased a new stake in shares of LAVA Therapeutics during the 3rd quarter worth about $32,000. BNP Paribas Financial Markets purchased a new stake in shares of LAVA Therapeutics during the 4th quarter worth about $40,000. Finally, Sanofi purchased a new stake in shares of LAVA Therapeutics during the 4th quarter worth about $1,825,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.